Potent inhibitory activity of Taniborbactam towards NDM-1 and NDM-1Q119X mutants, and "in vitro" activity of cefepime/taniborbactam against MBLsproducing Enterobacterales.
Sign Up to like & getrecommendations! Published in 2020 at "International journal of antimicrobial agents"
DOI: 10.1016/j.ijantimicag.2020.106228
Abstract: The main goal of the present study was to investigate the "in vitro" activity of taniborbactam (VNRX-5133), a novel broad-spectrum bicyclic boronate, against NDM-1 and Q119E, Q119K, Q119C, Q119F, Q119V and Q119Y NDM-1 variants which… read more here.
Keywords: taniborbactam; vitro activity; activity taniborbactam; activity cefepime ... See more keywords
Novel beta-lactamase inhibitors with cefepime: where do they fit in clinical practice?
Sign Up to like & getrecommendations! Published in 2025 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2025.2558990
Abstract: ABSTRACT Introduction Enmetazobactam, taniborbactam, and zidebactam are novel β-lactamase inhibitors that have been combined with cefepime in an effort to overcome common and emerging mechanisms of antimicrobial resistance. Areas covered We performed a literature review… read more here.
Keywords: clinical practice; cefepime; lactamase inhibitors; taniborbactam ... See more keywords
Burkholderia pseudomallei PenI β-lactamase and variants are potently inhibited by taniborbactam
Sign Up to like & getrecommendations! Published in 2025 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.00787-25
Abstract: ABSTRACT Burkholderia pseudomallei is a Gram-negative pathogen that causes melioidosis, a severe and often fatal disease. Due to its recognized potential as a bioterrorism agent, it is critical that appropriate antimicrobial agents are available for… read more here.
Keywords: lactamase; peni; cefepime mic; burkholderia pseudomallei ... See more keywords
In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program
Sign Up to like & getrecommendations! Published in 2022 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.01281-22
Abstract: Taniborbactam is a novel cyclic boronate β-lactamase inhibitor in clinical development in combination with cefepime. We assessed the in vitro activity of cefepime-taniborbactam and comparators against a 2018–2020 collection of Enterobacterales (n = 13,731) and Pseudomonas aeruginosa… read more here.
Keywords: activity cefepime; vitro activity; taniborbactam; cefepime taniborbactam ... See more keywords
The metallo-β-lactamases strike back: emergence of taniborbactam escape variants
Sign Up to like & getrecommendations! Published in 2024 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.01510-23
Abstract: ABSTRACT Metallo-β-lactamases (MBLs) have evolved relatively rapidly to become an international public health threat. There are no clinically available β-lactamase inhibitors with activity against MBLs. This may change with the introduction of cefepime-taniborbactam. Herein, we… read more here.
Keywords: 2024 https; agents chemother; https doi; metallo lactamases ... See more keywords
Cefepime-taniborbactam demonstrates potent in vitro activity vs Enterobacterales with blaOXA-48
Sign Up to like & getrecommendations! Published in 2024 at "Microbiology Spectrum"
DOI: 10.1128/spectrum.01144-24
Abstract: ABSTRACT Taniborbactam (formerly VNRX-5133) is a novel, investigational boronic acid β-lactamase inhibitor. The combination of cefepime (FEP) with taniborbactam is active against Enterobacterales carrying class A, B, C, and/or D enzymes. We assessed the activity… read more here.
Keywords: taniborbactam; clinical strains; fep taniborbactam; cefepime ... See more keywords